Akums Drugs &
Akums delivered a strong Q3 FY26 with operating revenue of ₹1,160 crore (+14.8% YoY) and EBITDA of ₹147 crore (+21% YoY), driven by 16% volume growth in CDMO and recovery in international branded formulations.
Akums Drugs & vs Eris Lifesciences Q3 FY26
Side-by-side earnings comparison across verified financials, sentiment, risks, and management commentary.
Eris Lifesciences
Eris Lifesciences reported Q1 FY26 consolidated revenue of ₹773 crore (+7.4% YoY) and PAT of ₹125 crore (+41% YoY), driven by strong domestic branded business (DBS) growth of 11% and margin expansion.
Result Snapshot
Revenue₹1,160 Cr₹807 Cr
PAT₹68 Cr₹109 Cr
EBITDA Margin12.7%35%
Sentimentbullishbullish
Key Quotes
Our healthy operating performance was characterized by strong execution across multiple key segments. CDMO registered a healthy topline growth of more than 16% driven by strong volumes.
We retain our position that we expect to be among the first launches in India post LOE.